Nashiha Shahid
Family Medicine · Batavia, NYNPI 1225140619
Payments from drug & device makers
Across 132 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$464
- Supernus Pharmaceuticals, Inc.$287
- Lilly USA, LLC$264
- Novo Nordisk$243
- Pfizer$176
- Bayer$171
- plus $989 from 17 others
What the payments were for
- Food & beverage$2,594100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 22 | $464 |
| Supernus Pharmaceuticals, Inc. | 9 | $287 |
| Lilly USA, LLC | 16 | $264 |
| Novo Nordisk | 12 | $243 |
| Pfizer | 15 | $176 |
| Bayer | 8 | $171 |
| AbbVie | 5 | $168 |
| Corium, LLC | 8 | $139 |
| Merck | 7 | $121 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Amgen | 4 | $83 |
| Boehringer Ingelheim | 3 | $69 |
| GSK | 3 | $58 |
| Ironshore Pharmaceuticals Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Exact Sciences | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Mission Pharmacal Company | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
How this compares
$2,594 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $22,575 |
| TrulicityDulaglutide | 17 | $22,263 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $15,729 |
| Duloxetine Hcl | 30 | $1,269 |
| Metoprolol Succinate | 53 | $995 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $738 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $628 |
| Pregabalin | 34 | $585 |
| Omeprazole | 19 | $521 |
| Montelukast Sodium | 31 | $455 |
| Cyclobenzaprine Hcl | 18 | $452 |
| Fluticasone Propionate | 16 | $414 |
| Levothyroxine Sodium | 36 | $364 |
| Losartan Potassium | 24 | $358 |
| Famotidine | 11 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $243 | $22,57523 claims |
| Lilly USA, LLCTrulicity | $264 | $22,26317 claims |
| GSKTrelegy Ellipta | $58 | $15,72913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Batavia
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.